Am­gen beefs up car­dio pipeline, adding a $673M RNAi deal with Ar­row­head

Last May, Ar­row­head Phar­ma­ceu­ti­cals CEO Chris An­za­lone turned up at a sci­en­tif­ic con­fer­ence in Nashville to talk up some of the com­pa­ny’s pre­clin­i­cal RNAi work on car­dio­vas­cu­lar dis­ease.

Work­ing with mice and mon­keys, in­ves­ti­ga­tors for the biotech demon­strat­ed that a sub­cu­ta­neous­ly de­liv­ered ther­a­py dubbed ARC-LPA demon­strat­ed some re­al po­ten­tial for knock­ing down lev­els of apolipopro­tein(a), a key com­po­nent of lipopro­tein(a), or Lp(a).

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.